Organic compounds -- part of the class 532-570 series inventions 12/08

20080319195 - Enantioselective preparation of benzimidazole derivatives and their salts: The invention relates to a new process for preparing benzimidazole derivatives having a chiral sulfoxide group in enantiomerically pure form or in a form in which one of the two enantiomers is present in an increased quantity over the other enantiomer. The invention likewise relates to a process for preparing... Agent: Smith Patent Consulting Consulting, LLC

20080319196 - Process for synthesizing remifentanil: An improved process for synthesizing opiate or opioid analgesics and anesthetics, and intermediates thereof is provided. In particular, processes of synthesizing intermediates for use in the preparation of synthetic opiate or opioid compounds such as, for example, remifentanil, carfentanil, sufentanil, fentanyl, and alfentanil are disclosed. The preparation process requires fewer... Agent: Mallinckrodt Inc.

20080319197 - Crystalline form of remifentanil hydrochloride: The present invention relates to a crystalline polymorphic form of remifentanil hydrochloride. The invention also describes methods of preparing a polymorphic form of remifentanil hydrochloride.... Agent: Mallinckrodt Inc.

20080319198 - Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias: e

20080312440 - Synthesis of drug conjugates via reaction with epoxide-containing linkers: The present invention relates to drug derivatives and linkers. The invention specifically relates to compounds and methods of phosphonates and linkers, that are useful as carriers for imaging agents and useful in the treatment of various bone diseases.... Agent: Hogan & Hartson L.L.P.

20080312441 - Use of oripavine as a starting material for buprenorphine: There is provided a method for the synthesis of norbuprenorphine, and ultimately buprenorphine, utilizing oripavine as the starting material. Conventional methods of producing buprenorphine utilize thebaine as the starting material, requiring an O-demethylation step, typically a low to moderate yield transformation. The present use of oripavine as a starting material... Agent: Mallinckrodt Inc.

20080312443 - Preparation of oxycodone: e

20080312442 - Process for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds: The present invention generally relates to processes for preparing highly pure morphinan-6-one products. The processes involve reducing the concentration of α,β-unsaturated ketone compounds present as impurities in morphinan 6 one products or reaction mixtures including morphinan 6 one compounds by treatment with a sulfur-containing compound. (A)... Agent: Mallinckrodt Inc.

20080312444 - Process for preparing bicyclic compounds: The present invention relates to a novel process for preparing compounds of formula (IA), which are potent and specific antagonists of corticotropin-releasing factor (CRF) receptors, from intermediate compounds of formula (I), by a coupling reaction catalysed by copper.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080312445 - Novel crystalline forms of nelfinavir mesylate: The present invention provides novel crystalline forms of Nelfinavir mesylate, Form-A, Form-B, Form-C, Form-D and the process for their preparation without the use of any special equipment such as a spray drier, avoiding the use of highly flammable solvents such as ethers. The crystalline form can be tailored with the... Agent: Schweitzer Cornman Gross & Bondell LLP

20080312446 - Imaging agents for diagnosis of parkinson's disease: Generally, the present invention is directed to central nervous system dopamine transporter-imaging agents and methods of use thereof. In certain embodiments, the present invention relates to radiolabeled piperidine derivatives for use as imaging agents in the diagnosis of Parkinson's disease. Another aspect of the present invention relates to piperidine monoamine... Agent: Foley & Lardner LLP

20080312447 - Process for isolation of crystalline tacrolimus: The invention is a simple process for separation of tacrolimus and its analogues, ascomycin and tsucubamycin B and preparation of enough pure crystalline tacrolimus. The process takes advantage of surprising properties of tacrolimus and involves extraction, purification and crystallization to produce purified crystalline tacrolimus.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20080312448 - Process for synthesizing remifentanil: A process for synthesizing remifentanil or carfentanil, as well as intermediates for use in the preparation of synthetic opiate or opioid compounds. The process comprising reacting a 4-amino 4-carbamyl piperidine with a base in a closed reaction chamber at elevated temperature and pressure to form to intermediate which may be... Agent: Mallinckrodt Inc.

20080312449 - New compounds: The novel optically pure compounds Na+, Mg2+, Li+, K+, Ca2+ and N+(R)4 salts of (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole or (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well... Agent: White & Case LLP Patent Department

20080312450 - Method for start-up of oxidation catalysts: Methods comprising: providing an oxidation catalyst bed; and starting up the oxidation catalyst at a temperature of 360° C. to 400° C. with an amount of air of 1.0 to 3.5 standard m3/h and a hydrocarbon loading of 20 to 65 g/standard m3, such that a hot spot having a... Agent: Connolly Bove Lodge & Hutz, LLP

20080306264 - Cycloolefin phosphine ligands and their use in catalysis: The present invention concerns novel bidentante optionally N-containing P-ligands of general Formula (I) embracing a two-ring-system and processes for synthesizing them, transition metal complexes of these compounds and their use as catalysts.... Agent: Law Office Of Michael A. Sanzo, LLC

20080306265 - Preparation of oxycodone: e

20080306266 - Process for preparing 2-methyl-1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine: The invention provides various processes for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine.... Agent: Edwards Angell Palmer & Dodge LLP

20080306267 - Method for making tetrabenazine compounds: A method of preparing a tetrabenazine compound (TBZ compound) having structure I comprising the steps of reacting a nucleophilic alkenyl species with aldehyde compound II and oxidizing the resultant allylic alcohol to provide enone III. The protecting group P1 on the tetrahydroisoquinoline nitrogen is removed and the resultant deprotected intermediate... Agent: General Electric Company Global Research

20080306268 - Crystalline clopidogrel hydrobromide and processes for preparation thereof: Provided are crystalline forms of clopidogrel hydrobromide and processes for their preparation.... Agent: Kenyon & Kenyon LLP

20080306269 - Intermediates useful for making tetrabenazine compounds: A method of preparing a tetrabenazine compound (TBZ compound) having structure I comprising the steps of reacting a nucleophilic alkenyl species with aldehyde compound II and oxidizing the resultant allylic alcohol to provide enone III. The protecting group P1 on the tetrahydroisoquinoline nitrogen is removed and the resultant deprotected intermediate... Agent: General Electric Company Global Research

20080306270 - Process for the preparation of a leukotriene antagonist and intermediates thereof: It comprises a preparation process of Montelukast from a new intermediate compound of formula (VI), which is previously prepared by reaction of the corresponding sulfonate with 1-(mercaptomethyl)cyclopropyl)methanol. Compound (VI) is reacted with a Grignard reactant to convert the ester group into a tertiary alcohol, followed by conversion of the primary... Agent: Berenbaum, Weinshienk & Eason, P.c

20080306271 - Novel process for production of highly pure polymorph (i) donepezil hydrochloride: The present invention provides a novel, industrially realizable and economically preferable process for production of highly pure 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methyl piperidine hydrochloride, i.e., donepezil hydrochloride shown in the following reaction scheme, in Polymorph (I) morphological crystal form. (I) In one of the key steps of the process, during the hydrogenation 5,6-dimethoxy 2-(pyridine-4-yhnethylene)indan-1-one... Agent: Hahn & Voight PLLC

20080306272 - One-pot methods for preparing cinnamide derivatives: e

20080306274 - Method for preparing n-aminopiperidine and its salts: The invention concerns a novel method for preparing N-aminopiperidine of formula (I):... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080306273 - Process for the preparation of 1-aminopiperidine derivatives: e

20080306275 - Novel heteroaryl derivative: (wherein Ring Z is an optionally substituted heteroaryl, R1 is a carboxyl group or an alkoxycarbonyl group, etc., W1 and W2 are an optionally substituted lower alkylene, Ar1 is an optionally substituted arylene or an optionally substituted heteroarylene, W3 is a single bond, a lower alkylene, a lower alkenylene, etc.,... Agent: Birch Stewart Kolasch & Birch

20080306276 - Facile synthesis of a series of liquid crystalline 2-(4'-alkoxyphenyl)-5-cyanopyridines: wherein CnH2n+1 is a linear alkyl group having 2-12 carbon atoms. The synthesis of the liquid crystalline 2-(4′-alkoxyphenyl)-5-cyanopyridine is completed in a two-step reaction. First, a Grignard reagent (such as 4-alkoxyphenylmagnesium bromide) is added to a 3-cyanopyridinium salt (such as N-phenyloxycarbonyl-3-cyanopyridinium chloride) to get a 1,2-dihydropyridine. Then, the 1,2-dihydropyridine is... Agent: Pai Patent & Trademark Law Firm

20080306277 - Process for preparation of chiral amlodipine gentisate: The present invention relates to a process for the preparation of optically pure amlodipine gentisate, more particularly to a continuous process for the preparation of optically pure amlodipine gentisate with good yield and high optical purity. The processes can be preformed by first reacting racemic (R,S)-amlodipine and optically pure O,O′-dibenzoyltartaric... Agent: Frommer Lawrence & Haug

20080306278 - Process: An improved process for preparing arylethanoldiamines is described. Compounds of this type are known to be useful as agonists at atypical beta-adrenoceptors (also known as beta-3-adrenoceptors).... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080300408 - Process for preparing a pure polymorphic form of 3-pyridyl-1-hydroxyethylidine-1, 1-bisphosphonic acid sodium salt: This process in general relates to the novel process for preparing polymorphic forms of 3-pyridyl-1-hydroxyethylidine-1,1-bisphosphonic acid sodium salt (Risedronate Sodium) in particular risedronate Form A and B employing a solvent system in an appropriate ratio. An improved process for preparation of risedronic acid is also disclosed in the present invention.... Agent: Workman Nydegger

20080300409 - Crystalline clopidogrel hydrobromide and processes for preparation thereof: Provided are crystalline forms of clopidogrel hydrobromide and processes for their preparation.... Agent: Kenyon & Kenyon LLP

20080300410 - Organic compounds: The present invention relates to salts of aryl compounds as discussed below and to methods of manufacture thereof, as well as other subject matter. More particularly, the invention relates to salts useful as intermediates for the synthesis of the cinnamanilide of formula (Y): where Ra is selected from H, OH,... Agent: Novartis Corporate Intellectual Property

20080300411 - Process for the preparation of the (s)-enantiomer of omeprazole: A process for the preparation of (S)-omeprazole from racemic omeprazole via the formation of an inclusion complex with (S)-1,1,2-triphenyl-1,2-ethanediol. (S)-Omeprazole is recovered in a substantially optically pure form either in neutral form or as a pharmaceutically acceptable salt or as its solvates including hydrates. The (S)-omeprazole 2[(S)-1,1,2-triphenyl-1,2-ethanediol] inclusion complex is... Agent: Berenbaum, Weinshienk & Eason, P.c